Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125

This study has been completed.
Sponsor:
Information provided by:
St Stephens Aids Trust
ClinicalTrials.gov Identifier:
NCT00792324
First received: November 14, 2008
Last updated: November 17, 2009
Last verified: November 2009
  Purpose

The purpose of the study is to examine the effect of switching from an antiretroviral combination that includes efavirenz (Susitiva®), in individuals experiencing efavirenz-related side effects, and replacing this with an investigational HIV medication called Etravirine (TMC125).

The study will primarily investigate the effect of change in medication on your viral load (the levels of the HIV virus in your blood), on immunological parameters (CD4 count), on other safety parameters (such as cholesterol) your side effects and also on your quality of life.


Condition Intervention Phase
HIV
Drug: Etravirine
Drug: Efavirenz
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Double Blind, Mulit-centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125.

Resource links provided by NLM:


Further study details as provided by St Stephens Aids Trust:

Primary Outcome Measures:
  • The rate of neuropsychiatric and central nervous system (CNS) toxicity as measured by the proportion of patients experiencing grade 2-4 neuropsychiatric and CNS toxicity after 12 weeks (as defined by the ACTG adverse event scale). [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The rate of neuropsychiatric and central nervous system (CNS) toxicity after 12 and 24 weeks as measured by the change from baseline by the Hospital Anxiety and Depression Scale (HADS). [ Time Frame: 12-24 weeks ] [ Designated as safety issue: Yes ]
  • Proportion of patients with viral load below 50 copies/mL at weeks 12 and 24 [ Time Frame: 12-24 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients with viral load below 400 copies/mL at weeks 12 and 24 [ Time Frame: 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in CD4+ count at weeks 12 and 24 [ Time Frame: 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in laboratory parameters at weeks 12 and 24 [ Time Frame: 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients with non-CNS adverse events at weeks 12 and 24 [ Time Frame: 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in adherence at weeks 12 and 24 as measured by the adherence questionnaire: Medication Adherence Self- Report Inventory (M-MASRI) [ Time Frame: 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in patient-perceived distress associated with tolerability problems at weeks 12 and 24 as determined by tolerability index questionnaire (HIV patients symptoms profile) [ Time Frame: 12 and 24 weeks ] [ Designated as safety issue: No ]

Enrollment: 24
Study Start Date: June 2008
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Group 1
Four 100mg Etravirine tablets plus one Efavirenz (EFV) placebo tablet once daily
Drug: Etravirine
Four 100mg tablets daily for 12-24 weeks
Other Names:
  • TMC125
  • Brand Name: Intelence
Active Comparator: Group 2
One 600mg EFV tablet plus four Etravirine placebo tablet tablets once daily
Drug: Efavirenz
One 600mg tablet daily
Other Names:
  • TMC125
  • Brand Name: Intelence

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented HIV-1 infection
  • Willing to comply with the protocol requirements
  • Has an HIV-plasma viral load at screening <50 HIV-1 RNA copies/mL
  • Has a CD4 cell count at screening >50 cells/mm3
  • Has been on a stable ART, with at least 3 licensed agents, one of which being EFV, for at least 12 weeks at screening, and is willing to stay on treatment until baseline
  • Symptomatic toxicity associated with the EFV after at least 12 weeks of therapy
  • If subject is female of childbearing potential, she is using effective birth control methods and is willing to continue practicing these birth control methods during the trial and for at least 30 days after the end of the trial (or after last intake of investigational ARV's)
  • If the subject is a heterosexually active male, he is using effective birth control methods and is willing to continue practicing these birth control methods during the trial and until 30 days after the end of the trial (or after the last intake of investigational ARVs)

Exclusion Criteria:

  • Subject has a primary HIV-1 infection
  • Subject has an HIV-2 infection
  • Subject is using any concomitant therapy disallowed by the protocol (as per SPC for EFV and TMC125)
  • Subject has any condition (including but not limited to alcohol and drug use) which, in the opinion of the investigator, could compromise the subject's safety or adherence to the protocol
  • Subject's life expectancy less than 6 months according to the judgment of the investigator
  • subject has a currently active AIDS defining illness (Category C conditions according to the Center for Disease Control [CDC] Classification System for HIV Infection 1993) with the following exceptions, which must be discussed with the sponsor prior to enrollment:
  • Stable cutaneous Kaposi's Sarcoma (i.e., no pulmonary or gastrointestinal involvement other than oral lesions) that is unlikely to require any form of systemic therapy during the trial period
  • Wasting syndrome due to HIV infection Note: Primary and secondary prophylaxis for an AIDS defining illness is allowed if the medication used is not part of the disallowed medication
  • Subject has any active clinically significant disease (e.g., pancreatic, cardiac dysfunction) or findings during Screening of medical history or physical examination that, in the investigator's opinion, would compromise the outcome of the trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00792324

Locations
United Kingdom
Chelsea and Westminster Hospital
London, United Kingdom, SW10 9TH
Sponsors and Collaborators
St Stephens Aids Trust
Investigators
Principal Investigator: Mark Nelson St Stephen's AIDS Trust
  More Information

No publications provided

Responsible Party: Dr Mark Nelson, St Stephens Aids Trust
ClinicalTrials.gov Identifier: NCT00792324     History of Changes
Other Study ID Numbers: SSAT 029
Study First Received: November 14, 2008
Last Updated: November 17, 2009
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Efavirenz
Etravirine
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 26, 2014